Risperidone can cause gynaecomastia — the benign enlargement of glandular breast tissue in males — through its well-established effect of raising prolactin levels. As one of the antipsychotics most strongly associated with hyperprolactinaemia, risperidone is widely used in the UK for schizophrenia, bipolar disorder, and certain specialist indications, yet its endocrine side effects are not always fully discussed with patients. This article explains the hormonal mechanism behind risperidone-induced gynaecomastia, who is most at risk, when to seek medical advice, and how it can be managed safely within UK clinical practice.

How Risperidone Affects Prolactin Levels

Risperidone blocks dopamine D2 receptors in the tuberoinfundibular pathway, removing the inhibitory control on prolactin release and causing sustained hyperprolactinaemia, a recognised adverse effect listed in its UK SmPC.

Experiencing these side effects? Our pharmacists can help you navigate them →

Risperidone is an atypical antipsychotic medication widely used in the UK for conditions including schizophrenia and bipolar disorder. It is also used in some specialist settings for behavioural disturbances in children and adolescents, including those associated with autism spectrum disorder, though this represents off-label use in the UK and should be initiated and supervised by a specialist. Risperidone works primarily by blocking dopamine D2 receptors and serotonin 5-HT2A receptors in the brain.

Dopamine normally acts as a prolactin-inhibiting factor, suppressing the release of prolactin from the pituitary gland. When risperidone blocks dopamine receptors — particularly in the tuberoinfundibular pathway — this inhibitory control is removed, leading to a sustained rise in circulating prolactin levels. This is known as hyperprolactinaemia, and it is listed as a recognised adverse effect in the UK Summary of Product Characteristics (SmPC) for risperidone-containing medicines, as documented on the MHRA/eMC database.

Risperidone is among the antipsychotics most associated with prolactin elevation. Unlike some other atypical antipsychotics such as quetiapine or clozapine, which have a lower affinity for D2 receptors and cause minimal prolactin elevation, risperidone is well recognised in clinical literature as producing marked increases in prolactin in a substantial proportion of patients. Paliperidone, the active metabolite of risperidone, shares this property. Elevated prolactin can affect multiple body systems, including the reproductive and endocrine systems, and is the primary mechanism through which risperidone may cause breast-related changes in both men and women.

The Link Between Risperidone and Gynaecomastia

Risperidone-induced hyperprolactinaemia stimulates glandular breast tissue growth and suppresses testosterone, directly causing true gynaecomastia; this association is recognised by the MHRA and EMA in the risperidone SmPC.

Gynaecomastia refers to the benign enlargement of glandular breast tissue in males, and it is a recognised adverse effect associated with risperidone use. The connection is directly related to the hyperprolactinaemia described above. Elevated prolactin stimulates breast tissue growth and can also suppress testosterone production by disrupting the hypothalamic-pituitary-gonadal axis. The resulting hormonal imbalance — raised prolactin alongside reduced testosterone — creates an environment that promotes the development of glandular breast tissue in men.

It is important to distinguish true gynaecomastia (glandular tissue proliferation) from pseudogynaecomastia (fatty tissue accumulation), as the latter is not hormonally driven. Risperidone-associated gynaecomastia typically involves genuine glandular tissue and may present with breast tenderness, swelling beneath the nipple, or a palpable disc of firm tissue.

This side effect is listed in the Summary of Product Characteristics (SmPC) for risperidone-containing medicines, as recognised by the MHRA and the European Medicines Agency (EMA). The association is well established in clinical literature and pharmacovigilance data. In some cases, gynaecomastia may improve if the medication is adjusted or discontinued, though this should only be done under medical supervision and with careful consideration of the patient's psychiatric stability.

How Common Is This Side Effect and Who Is at Risk

Gynaecomastia is classified as uncommon in the risperidone SmPC (fewer than 1 in 100 patients); adolescent males, those on higher doses, and long-term users are at greatest risk.

Gynaecomastia is classified as an uncommon adverse effect of risperidone in the UK SmPC (occurring in fewer than 1 in 100 but more than 1 in 1,000 patients). Hyperprolactinaemia itself occurs in a considerable proportion of patients taking risperidone — published studies suggest elevated prolactin levels are frequently observed, though reported rates vary depending on the population studied, the dose used, and the threshold applied — yet not all individuals with elevated prolactin will develop gynaecomastia.

Certain groups appear to be at higher risk:

• Adolescent males: Young men may be particularly susceptible due to already fluctuating hormone levels. Risperidone is used in this age group in specialist settings, making awareness especially important.

• Patients on higher doses: The degree of prolactin elevation is broadly dose-dependent, meaning those on higher doses face a greater risk.

• Long-term users: Prolonged exposure increases cumulative hormonal disruption.

• Individuals with pre-existing hormonal imbalances: Those with conditions affecting testosterone or oestrogen levels may be more vulnerable.

It is also worth noting that galactorrhoea (inappropriate milk production) can occur alongside gynaecomastia in males, further reflecting the degree of prolactin excess. Women taking risperidone may experience menstrual irregularities and breast changes as well, though gynaecomastia by definition applies to males. Clinicians should maintain a low threshold for investigating breast changes in any patient on long-term risperidone therapy. The Maudsley Prescribing Guidelines in Psychiatry and the BNF provide further guidance on monitoring and risk stratification.

When to Seek Medical Advice About Breast Changes

Any male on risperidone who notices breast swelling, tenderness, a firm lump, or nipple discharge should seek prompt medical advice; unexplained breast changes should be referred urgently under NICE NG12 to exclude malignancy.

Any male patient taking risperidone who notices changes in their breast tissue should seek prompt medical advice. Whilst risperidone-associated gynaecomastia is generally benign, it is essential to rule out other causes of breast enlargement. Although uncommon, male breast cancer requires timely assessment; in line with NICE NG12 (Suspected cancer: recognition and referral), clinicians should refer men with unexplained breast changes on a two-week-wait urgent pathway if cancer cannot be excluded on clinical grounds.

Patients or carers should contact their GP or prescribing clinician if they notice any of the following:

• Swelling or enlargement of one or both breasts

• Breast tenderness or pain, particularly around the nipple area

• A firm or rubbery lump beneath the nipple

• Nipple discharge (galactorrhoea)

• Skin changes over the breast, such as dimpling or redness

• Psychological distress related to physical changes, particularly in adolescents

It is important that patients do not stop taking risperidone without medical guidance, as abrupt discontinuation can lead to a return or worsening of the underlying psychiatric condition.

A GP or psychiatrist can assess whether the breast changes are consistent with drug-induced gynaecomastia and arrange appropriate investigations. These may include serum prolactin, testosterone, LH, FSH, oestradiol, TSH, and liver function tests, as well as a clinical breast examination and testicular examination to exclude other causes. If prolactin levels are markedly elevated or the patient reports headaches or visual disturbance — which may suggest a pituitary lesion — referral to endocrinology and consideration of pituitary imaging is warranted, in line with guidance from the Society for Endocrinology. Referral to a breast clinic may also be appropriate depending on clinical findings.

Managing Gynaecomastia While on Risperidone

Management begins with confirming the diagnosis via hormonal blood tests, then considering dose reduction or switching to a prolactin-sparing antipsychotic such as quetiapine or aripiprazole under specialist supervision.

Management of risperidone-induced gynaecomastia requires a careful, individualised approach that balances the benefits of antipsychotic treatment against the burden of side effects. The first step is confirming the diagnosis through clinical assessment and hormonal blood tests. Once drug-induced hyperprolactinaemia is identified as the likely cause, several management strategies may be considered.

Dose reduction is often the first approach, as lower doses may reduce prolactin elevation whilst maintaining therapeutic efficacy. Where clinically appropriate, switching to a prolactin-sparing antipsychotic — such as quetiapine or aripiprazole — may be considered. Aripiprazole acts as a partial dopamine agonist and can lower prolactin levels; it has been used as an adjunct to risperidone in some cases to mitigate hyperprolactinaemia. However, this adjunctive use is off-label and should be initiated and supervised by a specialist, with supporting evidence available in peer-reviewed literature and the Maudsley Prescribing Guidelines.

In cases where medication change is not feasible due to clinical stability, watchful waiting may be appropriate, particularly if gynaecomastia is mild and not causing significant distress. Dopamine agonists such as cabergoline have been used off-label to reduce prolactin levels, but their use carries a risk of worsening psychotic symptoms and must only be considered under close specialist supervision with careful monitoring of mental state.

For persistent painful gynaecomastia, tamoxifen has been used off-label following specialist assessment, though evidence in this specific context is limited. For severe or persistent gynaecomastia causing significant psychological or physical discomfort, surgical referral (subcutaneous mastectomy) may be considered as a last resort. Psychological support is also an important component of care, especially for adolescents and young adults, for whom body image concerns can be particularly distressing.

Guidance From the MHRA and Prescribing Considerations

The MHRA and EMA recognise gynaecomastia as a known risk of risperidone; NICE CG178 and the Maudsley Prescribing Guidelines recommend patient counselling, prolactin monitoring in high-risk groups, and reporting reactions via the Yellow Card scheme.

The Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency (EMA) both recognise hyperprolactinaemia and associated endocrine effects — including gynaecomastia — as known risks of risperidone. These are documented within the approved SmPC for risperidone-containing medicines available on the MHRA/eMC database.

NICE guidance on the management of psychosis and schizophrenia in adults (CG178) recommends that clinicians discuss the potential side effects of antipsychotic medication with patients before initiating treatment, and that ongoing monitoring of physical health forms part of routine care. Monitoring prolactin levels is particularly relevant for patients on risperidone; the Specialist Pharmacy Service (SPS) and the Maudsley Prescribing Guidelines advise considering baseline and follow-up prolactin measurement in patients on prolactin-raising antipsychotics, particularly if symptoms of hyperprolactinaemia emerge or in high-risk groups such as children and adolescents. Clinicians should follow local policy and use clinical judgement when deciding on the frequency of monitoring.

From a prescribing perspective, clinicians should:

• Counsel patients and carers about the possibility of breast changes before starting risperidone

• Consider checking prolactin levels at baseline and during treatment if symptomatic or in high-risk groups, in line with SPS/Maudsley guidance and local policy

• Document and review any reported breast changes at medication reviews

• Use the lowest effective dose to minimise endocrine side effects

• Report suspected adverse drug reactions via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk, which helps build the national evidence base for drug safety

Risperidone remains a clinically valuable medication for many patients, and the risk of gynaecomastia should not automatically preclude its use. However, informed prescribing, proactive monitoring, and open communication between clinicians, patients, and carers are essential to managing this side effect safely and effectively.

Frequently Asked Questions